论文部分内容阅读
目的研究国产瑞替普酶和尿激酶在治疗急性ST段抬高型心肌梗死中的治疗效果。方法 130例ST段抬高型心肌梗死患者,随机分为瑞替普酶组和尿激酶组,各65例。瑞替普酶组患者使用国产瑞替普酶静脉注射10 MU进行治疗,并每隔30 min进行1次等剂量注射;尿激酶组患者使用尿激酶150万U溶栓静脉滴注30 min。对比两组患者的临床治疗效果及各项激发症状。结果瑞替普酶组和尿激酶组患者临床再通率与血管再通率比较差异具有统计学意义(P<0.05),瑞替普酶组患者出血率虽低于尿激酶组,但差异无统计学意义(P>0.05)。两组死亡率、心源性休克等症状发生率比较差异无统计学意义(P>0.05)。结论在临床治疗ST段抬高型心肌梗死患者使用瑞替普酶,可提高临床治疗的安全性,有助于提高治愈率,可进行推广使用,在对并发症状方面,仍需要进行更多的临床实践来确保本药的确切疗效。
Objective To study the therapeutic effect of domestic reteplase and urokinase in the treatment of acute ST-segment elevation myocardial infarction. Methods One hundred and thirty patients with ST-segment elevation myocardial infarction were randomly divided into reteplase group and urokinase group, 65 cases each. The patients in the reteplase group were treated with 10 MU of intravenous reteplase and an equal dose injection every 30 minutes. Urokinase group was given intravenous infusion of 1.5 million U thrombus for 30 minutes. The two groups of patients were compared with the clinical effect and the excitation symptoms. Results There was significant difference between the rate of recanalization and recanalization rate in reteplase group and urokinase group (P <0.05). The hemorrhage rate in reteplase group was lower than that of urokinase group, but the difference was not significant Statistical significance (P> 0.05). There was no significant difference between the two groups in mortality and cardiogenic shock (P> 0.05). Conclusions The use of reteplase in patients with ST-segment elevation myocardial infarction may improve the safety of clinical treatment, improve the cure rate and promote the use of reteplase. In the case of concurrent symptoms, more Clinical practice to ensure the exact effect of the drug.